Gender Differences in Cytidine Deaminase Expression/Activity Contributes to Decreased Cytidine Analog Half-life and Likely Contributes to Worse Outcomes with 5-azacytidine or Decitabine Therapy – Author Reply

Samankaltaisia teoksia

• Increased CDA expression/activity in males contributes to decreased cytidine analogue half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy
  Tekijä: Mahfouz, Reda Z, et al.
  Julkaistu: (2013)
• High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
  Tekijä: Ebrahem, Quteba, et al.
  Julkaistu: (2012)
• A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer
  Tekijä: Sohal, Davendra, et al.
  Julkaistu: (2020)
• Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion
  Tekijä: Chilakala, Sujatha, et al.
  Julkaistu: (2019)
• The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes
  Tekijä: Murakami, Yuichi, et al.
  Julkaistu: (2019)